Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri Risk Communication Goes Beyond REMS With Monthly Update For Docs

Executive Summary

Biogen Idec's decision to start providing doctors with monthly updates on progressive multifocal leukoencephalopathy cases among Tysabri patients shows the firm's confidence that providing additional risk information will not discourage use of the product

You may also be interested in...



Tysabri Webcast Citation May Signal That FDA Could Treat All Social Media Interactions As Promotional; Biogen's PML Strategy Also Takes A Hit

FDA appears to be gearing up to treat social media interactions as promotional even when they are aimed solely at informing physicians

Tysabri Webcast Citation May Signal That FDA Could Treat All Social Media Interactions As Promotional; Biogen's PML Strategy Also Takes A Hit

FDA appears to be gearing up to treat social media interactions as promotional even when they are aimed solely at informing physicians

Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June

Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel